A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine andidate, is now underway in seven African countries.
The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers
announced late Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference underway in Nairobi.
The trial is underway in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania.
The health experts were optimistic that the malaria vaccine could be made available to African governments by the year 2012.
Sirima Sodiomon of the National Centre for Research and Malaria Training in Burkina Faso said that the vaccine targeted the African continent because it was the most prone to the Malaria epidemic.
He said the efficacy rate of the vaccine was expected to be about 30-50 percent. "We need to continue with the research and may be the second
generation vaccine which may come up in five to six years may have a higher efficacy rate of about 80-90 percent," Sodiomon said.
He said researchers were now on the third phase of trials which was the most crucial and involved large number of people for the clinical tests and this would have 16,000 children, 5,000 of whom would be from Kenya.
"Vaccines are one of the best ways to protect against any disease but currently we don't have any efficacy vaccine but at least we hope to have
this one which will protect from 30-50 percent and then compliment it with other strategies like bed nets," the medic said.
GlaxoSmithKline Biologicals' (GSK Bio) RTS,S is the first malaria vaccine candidate to demonstrate significant efficacy during early
development to warrant Phase III testing.
It is the leading vaccine candidate in the global effort by the PATH Malaria Vaccine Initiative (MVI) to develop a malaria vaccine.
"A malaria vaccine could help save countless lives and redefine the future for Africa's children," said Dr. Patricia Njuguna, RTS, S principal investigator (KEMRI-Wellcome Trust, Kilifi, Kenya) and chair of the Clinical Trials Partnership Committee, a collaboration of African research institutions, MVI, and GSK Bio that is leading the clinical development of RTS,S.
"Communities all across Africa are dedicated to this future and are participating to ensure that we develop a vaccine with an acceptable safety and efficacy profile."
RTS,S is the first vaccine designed primarily for use in Africa, where malaria kills more than 800,000 people every year, the majority of them
children under the age of five.
By conducting the trial in seven different countries across Sub- Saharan Africa, researchers will be able to evaluate the vaccine candidate's
efficacy in a variety of settings, with diverse patterns of malaria transmission.
For example, some trial sites are located in areas where there is a year-round threat of malaria, while others experience only seasonal
transmission.
All of the research centers were chosen for their track record of world-class clinical research, strong community relations and commitment to meeting the highest international ethical, medical, clinical and regulatory
standards.
"This is a tremendous moment in the fight against malaria and the culmination of more than two decades of research, including 10 years of
clinical trials in Africa," said Joe Cohen, co-inventor of RTS,S and Vice President of R&D, Vaccines for Emerging Diseases and HIV, at GSK
Biologicals.
"The Phase III trial is a huge undertaking that depends on effective coordination between researchers, regulators, families and communities.
Everyone involved has invested significant energy and resources to pave the way for what could become the world's first malaria vaccine."
Recent Phase II studies showed that RTS,S reduced clinical episodes of malaria by 53 percent over an eight-month follow-up period.
Findings from a Phase II trial initiated in 2002 and conducted with more than 2,000 children in southern Mozambique, published in the medical
journal The Lancet in 2004 and 2005, showed that RTS,S was efficacious for at least 18 months in reducing clinical malaria by 35 percent, and severe malaria by 49 percent.
In addition, RTS,S was shown to have a promising safety and tolerability profile when used alongside the World Health Organization's
(WHO) standard infant vaccines.
"This historic trial could lead to the availability of a vaccine with the potential to save the lives of hundreds of thousands of African
children, if the data are positive," said Dr. Christian Loucq, director of the PATH Malaria Vaccine Initiative.
"But development is only half the mission; MVI and its partners are committed to ensuring this vaccine reaches those who need it most. We hope the international community will respond by starting to prepare for the day when--if all goes well--this vaccine will be available for distribution and use."
The Phase III trial will evaluate the vaccine's efficacy in two groups of children. One group, aged 6 to 12 weeks, will be vaccinated as part of their regular schedule of infant immunizations; the second group includes children aged 5 to 17 months.
The vaccine profile is intended primarily for infants, as they and children under the age of five are the most vulnerable to malaria.
"This is the largest trial ever conducted in Africa of a vaccine specifically designed for use with African children. We have great appreciation for the families and children participating," said Dr. Salim Abdulla, director of the Ifakara Health Institute, Tanzania, which is participating in the Phase III trial.
"Development of RTS,S across Africa has strengthened our research capacity, a legacy that will far outlast the trials."
Each country hosting a study site has undertaken independent reviews to ensure the trial meets national safety, ethical and legal standards for medical research.
In addition, an independent data and safety monitoring board oversees the entire trial with support from local safety monitors.
The trial has been designed in consultation with appropriate regulatory authorities in the European Union, the United States and African countries, in conjunction with the WHO.
Under current plans, the RTS,S vaccine candidate would be submitted to regulatory authorities in 2012 based on efficacy in children 5-17 months of age.
Additional safety and immunogenicity data from the infant population will be submitted soon thereafter, followed by efficacy data for infants
once available.
Depending on the final clinical profile of the vaccine and the timetable of the regulatory review process, the first vaccine introduction
could take place over the next three to five years.
"GSK's approach is to make every effort possible to accelerate the availability of this life-saving vaccine," said Mr. Jean Stéphenne,
President and General Manager, GlaxoSmithKline Biologicals.
"Ever conscious of the burden of malaria, we have no time to lose and we will exhaust every avenue at our disposal. This is our commitment as a company."